Novartis pushes ahead with agomelatine in the US
This article was originally published in Scrip
Executive Summary
Novartis, the US licensee of Servier's once-daily antidepressant, agomelatine (AG0178), says that it now expects to file for US approval of the product in 2012, after the conclusion of additional Phase III clinical trials.